Bredt David
Rapport Therapeutics, Inc. Common Stock · Chief Scientific Officer
Bredt David is listed in filings as Chief Scientific Officer at Rapport Therapeutics, Inc. Common Stock. This profile follows SEC Form 4 activity through Feb 19, 2026, including sale activity. Recent filings connect the profile to Rapport Therapeutics, Inc. Common Stock (RAPP). The current snapshot covers public activity from Feb 4, 2025 to Feb 19, 2026. Reported amounts are shown as $10.8K to $65.1K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.